Key Highlights

  • QuidelOrtho (NASDAQ:QDEL) closed at USD 14.21 on Tuesday, October 20, 2026, up 11.52% on about 1.90 million shares, after falling 7.19% to USD 12.91 on Friday, October 16.
  • The company had not issued a release accounting for either move as of Wednesday, October 21, 2026, when the shares traded near USD 14.42 early in the session.
  • Trailing earnings per share stand at a loss of about USD 15.41 in market data, so the 122.63% EPS change in a screen of small caps is computed on a negative base.
  • At a market value near USD 990 million, the shares trade at about 0.33 times trailing sales, far below a historical median of about 2.88 times in market data.

What Moved the Shares This Week

QuidelOrtho (NASDAQ:QDEL) makes diagnostic tests and laboratory analysers used by hospitals, clinics and blood banks. The shares closed at USD 14.21 on Tuesday, October 20, 2026, up 11.52% on volume of about 1.90 million shares. That followed a 7.19% fall to USD 12.91 on Friday, October 16, 2026. The company had not issued a release accounting for the move as of Wednesday, October 21, 2026, so the rebound appears to reflect trading in a heavily sold stock rather than new information. Early in the session on Wednesday the shares traded near USD 14.42, up about 1.46%. The 52-week range runs from roughly USD 9.37 to USD 9.92 at the low end to about USD 35.08 to USD 35.58 at the high.

Why the EPS Growth Figure Does Not Signal a Recovery

For QuidelOrtho (NASDAQ:QDEL), the 122.63% EPS change is computed on a negative base, so it does not mean profits have risen. A trailing loss of about USD 15.41 per share compares with a share price near USD 14, which is a market-pricing inference pointing to large non-cash charges, such as asset write-downs, rather than cash losses of that size. Published market data also describe declining revenue per share, weaker margins and rising debt. The price to sales ratio of about 0.33 times, against a historical median near 2.88 times, shows how far the market has marked down expected profitability. The classification is a loss base with no evidence yet of durable operating improvement. Insider purchases of about USD 1.3 million over the past year are a modest offsetting signal.

Risks and What to Watch

The main risk for QuidelOrtho (NASDAQ:QDEL) is that weaker margins and rising debt continue to erode equity value, because leverage magnifies small changes in operating profit. Interest costs are a related risk while the 10-year Treasury yield sits near 5.12% and the Federal Reserve has resumed rate increases. Volatility itself is a third risk: daily moves of 7% to 12% without company news show positioning, not fundamentals, driving the price. Investors should watch the third-quarter report, expected in early November on the usual calendar, for revenue trends, margin direction and debt reduction. The Federal Reserve decision on Wednesday, October 28, 2026 also bears on financing costs for leveraged small caps.

Where Things Stand

The answer is that QuidelOrtho (NASDAQ:QDEL) jumped 11.52% without a company release, most likely as a rebound after a 7.19% fall. The 122.63% EPS change is computed on a trailing loss of about USD 15.41 per share and does not indicate a profit recovery. The valuation of about 0.33 times sales shows deep scepticism. The next catalysts are third-quarter results, debt and margin trends and the October 28 Federal Reserve decision. Market data can differ by provider, and this is not investment advice.